Skip to main content
Premium Trial:

Request an Annual Quote

Hey, It Makes You Better. Do We Really Need to Know More than That?

Omics! Omics! has a post on recent news from Millennium that "their Phase III trial for Velcade in newly diagnosed multiple myleoma had halted early because the experimental arm was performing so much better than the control arm," writes Keith Robison, who used to work at Millennium. He goes on to talk about the "therapeutic ignorance" at companies involved in drug discovery and development; the biology of what's really going on is often not fully understood even when drugs are on the market. Robison asks, "Will we ever move from incremental, conservative, empirical approaches to some rational, mechanistic hypothesis-driven approach?" In his view, he's hopeful that it will eventually happen, but says that in the near term it remains highly unlikely.

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.